Author Archives: admin


MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA | Antibodies | News Channels -…

DetailsCategory: AntibodiesPublished on Monday, 30 December 2019 14:42Hits: 67

PLANEGG/MUNICH, Germany I December 30, 2019 I MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tafasitamab, an anti-CD19 antibody, for the treatment of relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL). The BLA submission is based on the primary analysis data from the L-MIND trial of tafasitamab in combination with lenalidomide in patients with r/r DLBCL and the retrospective observational matched control cohort Re-MIND evaluating efficacy outcomes of r/r DLBCL patients who received lenalidomide monotherapy.

"The BLA submission marks a significant milestone in MorphoSys' history and demonstrates our dedication to address the high medical need in relapsed or refractory DLBCL," said Dr. Malte Peters, Chief Development Officer of MorphoSys. "If approved, tafasitamab and lenalidomide could become an alternative treatment option for patients with this serious disease."

The FDA has a 60-day filing review period to determine whether the BLA is complete and acceptable for filing. MorphoSys will communicate the agency's decision.

About L-MINDL-MIND is a single arm, open-label phase 2 study, investigating the combination of tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL) after up to two prior lines of therapy, including an anti-CD20 targeting therapy (e.g. rituximab), who are not eligible for high-dose chemotherapy and subsequent autologous stem cell transplantation. The study's primary endpoint is objective response rate (ORR). Secondary outcome measures include duration of response (DoR), progression-free survival (PFS) and overall survival (OS). In May 2019, the study reached its primary completion. Primary analysis data with a cut-off date of November 30, 2018 included 80 patients enrolled into the trial who had received tafasitamab and lenalidomide and had been followed-up as per protocol for at least one year. Efficacy results in this update were based on response rates assessed by an independent review committee for all 80 patients. Based on earlier reported interim data from L-MIND, in October 2017 the U.S. FDA granted Breakthrough Therapy Designation for tafasitamab plus lenalidomide in this patient population.

About Re-MINDRe-MIND, an observational retrospective study, was designed to isolate the contribution of tafasitamab in the combination with lenalidomide and to prove the combinatorial effect. The study compares real-world response data of patients with relapsed or refractory DLBCL who received lenalidomide monotherapy with the efficacy outcomes of the tafasitamab-lenalidomide combination, as investigated in MorphoSys's L-MIND trial. Re-MIND collected the efficacy data from 490 r/r DLBCL patients in the U.S. and EU. Qualification criteria for matching patients of both studies were pre-specified. As a result, 76 eligible Re-MIND patients were identified and matched 1:1 to 76 of 80 L-MIND patients based on important baseline characteristics. Objective response rates (ORR) were validated based on this subset of 76 patients in Re-MIND and L-MIND, respectively. The primary endpoint of Re-MIND has been met and shows a statistically significant superior best ORR of the tafasitamab/lenalidomide combination compared to lenalidomide monotherapy.

About tafasitamab (MOR208)Tafasitamab (MOR208) is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. Fc-modification of tafasitamab is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. Tafasitamab has been observed in preclinical models to induce direct apoptosis by binding to CD19, which is assumed to be involved in B cell receptor (BCR) signaling.MorphoSys is clinically investigating tafasitamab as a therapeutic option in B cell malignancies in a number of ongoing combination trials. An open-label phase 2 combination trial (L-MIND study) is investigating the safety and efficacy of tafasitamab in combination with lenalidomide in patients with relapsed/refractory DLBCL who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Based on interim data from L-MIND, in October 2017 the U.S. FDA granted Breakthrough Therapy Designation for tafasitamab plus lenalidomide in this patient population. Re-MIND, the real-world data lenalidomide alone matched control cohort met its primary endpoint in October 2019, demonstrating clinical superiority of the tafasitamab/lenalidomide combination compared to lenalidomide alone. The ongoing phase 3 study B-MIND assesses the combination of tafasitamab and bendamustine versus rituximab and bendamustine in r/r DLBCL. In addition, tafasitamab is currently being investigated in patients with relapsed/refractory CLL/SLL after discontinuation of a prior Bruton tyrosine kinase (BTK) inhibitor therapy (e.g. ibrutinib) in combination with idelalisib or venetoclax.

About MorphoSysMorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 28 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, tafasitamab (MOR208), has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 405 employees. More information at https://www.morphosys.com.

SOURCE: Morphosys

Read the original:
MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA | Antibodies | News Channels -...

All the feels: From start to finish, a year of emotional stories – Golf Channel

No matter how packed with all that makes the game greata golf year might be and Id contend that theres never been a year that wasnt it wont stand out in history unless it has one extra special moment. And 2019 had that.

Golfs broad strokes rarely cut as wide a swath through culture as the Big 3 team sports, but Tiger Woods victory at the Masters was voted The Associated Presss top sports story of the year. Its importance may come to be considered greater than his 1997 Masters victory, or his U.S. Open wins at Pebble Beach in 2000 and Torrey Pines in 2008. And as a comeback from adversity, Woods first major victory in 11 years at least rivals and arguably surpasses not only Ben Hogans 1950 U.S. Open, but ANY sports comeback ever. It was extra special.

But so much else happened in 2019. What to make of the rest?

Well, lets start with Woods. Its easy to forget that a lot of things had to go just right on Sunday for Tiger to win at Augusta. And that as much as the place is considered his sweet spot, he hadnt won there since 2005. For me, the singular moment that meant more going forward was the Zozo Championship in November. Not because it became Woods record-tying 82nd career. And despite the tournament being a limited field, off-season event over a short golf course in a faraway land.

Was there any doubt? For our No. 1 Storyline of the Year, we look back on Tiger Woods' 15th major title at the Masters Tournament.

It was the WAY that Tiger played with a return to an ease and smoothness in his action that not only recalled much earlier days, but which promises repeatability and consistency. As well as on the right occasions dominance.

Next on the hit parade the education of Rory McIlroy. The four-time major winner added important elements to his game namely better putting and overall ball control to set the foundation for another sustained run of greatness in his 30s.

But it was also a year of searching. McIlroy came into 2019 reflective and open to new ideas. He said meditation, juggling and several self-help books had led him to decide that he would no longer allow my score to define who I am as a person. His consistency improved and he impressively won The Players in March. But McIlroy also had several flattish Sundays with chances to win, and the Masters where he continues to chase the career Grand Slam didnt go so well.

Prior to the U.S. Open, McIlroy roared to a seven-shot win in Canada. But he tied for ninth at Pebble Beach. Expectations were again high at Portrush, a short car ride from his boyhood home and where he had shot the course record of 61 at age 16. He opened The Open with a nervous 79 and missed the cut. The next week he got boat-raced by winner Brooks Koepka in a final Sunday pairing at the WGC-FedEx in Memphis.

It was again time to reassess.

After winning the FedExCup at East Lake, this time outplaying Koepka in the last group in what he would later call the highlight of his year, McIlroy revealed having committed to a harder and more self-aware competitive edge.

I think one of the biggest things is sometimes Ive tried to treat Sundays the same as a Thursday or Friday, and theyre not, said McIlroy, who would go on to win WGC-HSBC in Shanghai in November for his fourth victory of the year. Ive gone into them maybe a little too relaxed, but its not the same, and its about trying to get yourself in the right mindset. I guess thats the ultimate compliment I can give Brooks is that I wanted to be a little bit more like him.

McIlroy on Koepka rivalry: Feels good to take down No. 1

Speaking of Big Game Brooks, his ruthless march through the major championships since 2017 has been undervalued. In the last 30 years, only Woods, McIlroy and Nick Faldo have had such prolonged periods of excellence in the biggest events.

This year, Koepka showed true dominance in building a seven-stroke lead through three rounds in his victory at the PGA at Bethpage. That he bookended that performance with seconds at the Masters and at the U.S. Open got short shrift. And after he finished fourth at Portrush, when his putter uncharacteristically failed him (and he was being bothered by a torn patella tendon in his left knee that required stem cell treatment and from which he is still recovering), too many acted as though his reign had ended.

That impression was strengthened when McIlroy was chosen as PGA Tour Player of the Year by a vote of his peers. In the last couple of years, Koepka has used relatively small slights for fuel. But going into 2020 and turning 30 in May, he will be on a mission to strengthen his hold on world No. 1 and outdo McIlroy in the process. Koepka betrayed some saltiness in October by pointing out that, Ive been out here for what, five years. Rory hasnt won a major since Ive been on the PGA Tour. So I dont view it as a rivalry.

Sounds like a rivalry.

Although Jon Rahm, who enters 2020 at No. 3 in the world, is expected to intrude.

The 25-year-old Spaniard earns the description beast in the same way as team sport athletes who appear physically overwhelming. Along with his nine combined victories on the PGA and European tours, Rahm has also validated his combination of power and touch with a relentless consistency in his first 89 official worldwide professional starts, Rahm has 44 top-10s, only one less than Woods in his first 89. As he continues to mature and he got married just this month expect a calmer, more controlled Rahm to be even more dangerous.

In the womens game, Jin Young Ko was by far the best player of the year, winning two majors and two other events in only her second season on the LPGA tour. In a gracious acceptance speech for year-end honors at the tours awards banquet, the 24-year-old South Koreans accented, but precise English reflected the same discipline and exactitude that is so evident in her game. The current Rolex No. 1 knows thats been a precarious perch over the last decade in womens golf, and she seems determined to change the cycle. This is not the end, she told the gathering, but only the beginning.

Ok, thats the highest profile stuff. But there was also a pervasive theme that permeated 2019. In so many ways, it was an extraordinarily feel-good year.

Usually in these end-of-the-year assessments, what sticks with me most and reinforces my generally tragic sense of competitive golf are the deeply wounding, self-induced losses brought on by late implosions. You know, Phil Mickelson at Winged Foot, Adam Scott at Royal Lytham & St. Annes, and Jordan Spieth at the 2016 Masters with plenty of other examples to stuff into the hurt locker. But as I remember 2019, only two players caused such sadness, Francesco Molinari at the Masters and Lizette Salas at the Womens British Open. Molinari, the seemingly unflappable ball-striking machine led by two strokes on the 12th tee Sunday at the Masters before mishitting an 8-iron into Raes Creek, opening the door for Woods. Salas, who played the best golf of her life with a closing 65 at Woburn, missed a 5-foot birdie putt on the 72nd hole, and then watched Hinako Shibuno win it with a 20-footer.

Instead of a bevy of heartbreak, we got a full complement of Capra-esque moments.

Winning putt: Pettersen clinches the Solheim Cup for Europe

Suzann Pettersen, after making an 8-footer on the final green in the last match that spelled the difference between winning and losing the Solheim Cup, announced her retirement at age 38. One of the great walk-offs ever in professional sports. Pettersen said she reached the decision spontaneously with the thought, This is it. This is the peak.

Shane Lowry, as an underachiever scarred by a Sunday failure at the 2016 U.S. Open, shouldering the immense mental load before thousands of home fans in a land that hadnt held the Open Championship since 1951, and winning by six. The panorama on Portrushs 72nd hole, with fansrunning up the fairway behind Lowry, some waving Irish flags in the rain amid a constant roar, was one of pure cathartic release.

Shibuno winning the Womens British Open at Woburn in her first professional tournament outside Japan. A babe in the woods at 20, she was bolstered by innocence and a constant, infectious smile, even as she four-putted early in the final round. Shibunocaught fire and closed with a 31 on the final nine, her final putt rammed in with a blissful freedom, to become the second Japanese player to win a major championship.

The scene at the inaugural Augusta National Womans Amateur, where the image of women striding the hallowed grounds was a transformative moment for the game. The impressive brand of head-to-head power golf played by winner Jennifer Kupcho and runner-up Maria Fassi was the icing on the cake.

The effervescent Helen Alfreddson winning the second U.S. Senior Womens Open at Pine Needles, the most joyous, about time and appreciated championship in golf. Love of the game is never more palpable than among too-long-ignored 50-and-over LPGA veterans, and Alfreddsons passion and exuberance spoke for them all.

Cameron Champ won the Safeway Open in October while dedicating his play to his gravely ill African-American grandfather, Mack, who started him in the game. The 24-year-old bombers calm as he garnered his second victory was reminiscent of Ben Crenshaws march to the 1995 Masters after being a pallbearer at the funeral of his teacher, Harvey Penick, earlier that week.

In the most exciting finish of the year, Matthew Wolff he of the fascinatingly powerful swing and unofficial leader of the games latest youth movement in only his third pro start, won the 3M Championship with an eagle on the 72nd hole to beat Bryson DeChambeau, who had also eagled the last, by one.

Finally and excuse my darkness Koepka and Rahm saving big victories after blowing huge Sunday leads. For some reason, nothing makes me happier (or more accurately relieved) than seeing a player who has gone from the zone to full meltdown, and then reverse what suddenly looks like his or her inevitable and awful fate in the nick of time. Koepka dug to the very bottom of his deep reservoir of poise to do it at Bethpage after four straight bogeys on the final nine had him lose all but one of his seven-stroke lead. Rahm had a five shot lead with 10 to play at the DP World in Dubai, but it was all gone thanks especially to a couple of knuckleheaded three-putts from inside 25 feet when he reached the 72nd hole. Hell remember that birdie with a smile and a shudder for the rest of his life.

Adding additional poignancy to our main theme, it was also the year of journeymen each capable, but with a history of struggle at the highest level seizing the day.

There is a fine line between success and slump in professional golf. It took only one swing to send Brendon Todd over that line and years to make it back.

Brendan Todd ran away with this category, returning from nearly four years in the wilderness that included a stretch of missing 37 of 41 cuts, to win back-to-back at Bermuda and Mayakoba, and then nearly won again at the RSM. The 34-year-old, who won the Byron Nelson in 2014, came down with a nightmare dose of the swing yips (the lose-it-way-right strain) that by late-2018 had him on the verge of giving up pro golf and opening a pizza franchise. Instead, Todd got some help from swing coach and former player Bradley Hughes and pulled off one of the great turnarounds in golf history.

And consider this roll call of others who went through storybook lost-and-found cycles to convert a week of magic into first victories that take them into 2020 with transformed lives: Max Homa (Wells Fargo Championship), JT Poston (Wyndham Championship), Nate Lashley (Rocket Mortgage), Lanto Griffin (Houston Open), Tyler Duncan (RSM Classic), Adam Long (Desert Classic). Inspirations all.

And at the risk of belaboring the feel-good point, it seemed that just about every level of pro golf ended the year on a happy note.

At the PGA Tours finale at East Lake, McIlroy spread much joy in Ponte Vedra, with one fell swoop validating the wisdom of the Tours more compressed and earlier finishing schedule, getting the new staggered start scoring system at the Tour Championship off on the right foot, and winning in the final group in another showdown with Koepka.

The LPGAs season ended on a high note with Sei Young Kim making a 22-foot birdie putt on the last hole to win the richest first-place prize ever in the womens game $1.5 million at the CME Group Tour Championship. A new format had been questioned for seeming to put sheer money over an equitable reward for season-long performance, but Kims stature as a top player and the cliffhanger nature of her victory over Charley Hull made for a satisfying result.

The PGA Tour Champions season ended with a bang when Jeff Maggert holed out from 123 yards for eagle to win the Charles Schwab Cup Championship in sudden-death.

And at the last big event of the year, the Presidents Cup, Woods was fittingly triumphant as both captain and player. And, as he has done more with age, a strong display of emotion spread the joy.

So finally, did something happen that set the tone for all this happiness? Was there a beginning?

Amy Bockerstette, a 20-year-old golfer with Down syndrome, got to play the iconic 16th hole at the Waste Management Phoenix Open and made par with Gary Woodland watching.

To say there wasnt would be to underestimate the impact of Amy Bockerstette, a 20-year-old collegiate golfer and Special Olympics athlete with Down syndrome, who in January played the 16th hole with Gary Woodland at the pro-am of the Waste Management Phoenix Open. Ill admit it, tears fill my eyes each time I watch the 2-minute and 50-second video, which has reached double-digit million views.

Seeing the way Bockerstette, clearly thrilled to meet her playing partners, Woodland and Matt Kuchar, reveled so genuinely as the center of attention on golfs iconic stadium hole, and then stepped up, assertively telling herself, I got this, is irresistible. She hit a good tee shot, followed with a deft bunker shot, and then, again repeating her mantra out loud, drilled the 10-footer for par with Nicklausian poise.

One guess at the phrase Woodland told himself before pulling off the shot of the year a perfectly clipped 60-degree wedge off the 17th green at Pebble Beach that carried and spun to within 4 feet and a crucial par.

Said Woodland of Bockertette: Theres nobody that Ive seen be in the moment as much as she is.

In a particularly feel-good year, it might have been the most extra special moment of all.

View original post here:
All the feels: From start to finish, a year of emotional stories - Golf Channel

Michael Schumacher update: How is Michael Schumacher doing – six years on? – Express.co.uk

Speaking to Shes Mercedes magazine last month, she said: He is in the best of hands right now and we are doing everything we can to help him.

Try to understand that we follow Michaels desire to keep his health a secret.

You can be sure that he is in the very best of hands and that we are doing everything humanly possible to help him.

Please understand if we are following Michaels wishes and keeping such a sensitive subject as health, as it has always been, in privacy.

Michael Schumachers fans have honoured Corinnas request, as Reiner Ferling, chairman of the Kerpen fan club, said they would provide all kinds of support.

He said: Unfortunately, the time has come again, the sixth anniversary of Michaels accident is coming around.

Six years full of hope that Michael will one day go out in public again. We know that Michael is in good hands, that he gets love, security and confidence.

Michael can count himself lucky to have such a strong family behind him.

Visit link:
Michael Schumacher update: How is Michael Schumacher doing - six years on? - Express.co.uk

Brain tumor organoids may be key to time-sensitive treatments for glioblastomas – Science Codex

PHILADELPHIA --Lab-grown brain organoids developed from a patient's own glioblastoma, the most aggressive and common form of brain cancer, may hold the answers on how to best treat it. A new study in Cell from researchers at Penn Medicine showed how glioblastoma organoids could serve as effective models to rapidly test personalized treatment strategies.

Glioblastoma multiforme (GBM) remains the most difficult of all brain cancers to study and treat, largely because of tumor heterogeneity. Treatment approaches, like surgery, radiation and chemotherapy, along with newer personalized cellular therapies, have proven to slow tumor growth and keep patients disease-free for some periods of time; however, a cure remains elusive.

"While we've made important strides in glioblastoma research, preclinical and clinical challenges persist, keeping us from getting closer to more effective treatments," said senior author Hongjun Song, PhD, Perelman Professor of Neuroscience in the Perelman School of Medicine at the University of Pennsylvania. "One hurdle is the ability to recapitulate the tumor to not only better understand its complex characteristics, but also to determine what therapies post-surgery can fight it in a timelier manner."

Co-senior authors include Guo-li Ming, MD, PhD, Perelman Professor of Neuroscience, and Donald O'Rourke, MD, the John Templeton, Jr., MD Professor in Neurosurgery, and director of the GBM Translational Center of Excellence at Penn's Abramson Cancer Center.

Lab-grown brain organoids -- derived from human pluripotent stem cells or patient tissues and grown to a size no bigger than a pea -- can recapitulate important genetic composition, brain cell type heterogeneity, and architecture, for example. These models are allowing researchers to recreate key features of patients' diseased brains to help paint a clearer picture of their cancer, and allowing them to explore ways to best attack it.

What makes organoids so attractive in GBM is timing and the ability to maintain cell type and genetic heterogeneity. While existing in vitro models have added to researchers' understanding of the biological mechanisms underlying the cancer, they have limitations. Unlike other models, which need more time to exhibit gene expression and other histological features that more closely represent the tumor, brain tumor organoids developed by the research group grow into use much more rapidly. That's important because current treatment regimens are typically initiated one month following surgery, so having a road map sooner is more advantageous.

In the new study, the researchers removed fresh tumor specimens from 52 patients to "grow" corresponding tumor organoids in the lab. The overall success rate for generating glioblastoma organoids (GBOs) was 91.4 percent, with 66.7 percent of tumors expressing the IDH1 mutation, and 75 percent for recurrent tumors, within two weeks. These tumor glioblastoma organoids can also be biobanked and recovered later for analyses.

Genetic, histological, molecular analyses were also performed in 12 patients to establish that these new GBOs had largely retained features from the primary tumor in the patient.

Eight GBO samples were then successfully transplanted into adult mouse brains, which displayed rapid and aggressive infiltration of cancer cells and maintained key mutation expression up to three months later. Importantly, a major hallmark of GBM -- the infiltration of tumor cells into the surrounding brain tissue -- was observed in the mouse models.

To mimic post-surgery treatments, the researchers subjected GBOs to standard-of-care and targeted therapies, including drugs from clinical trials and chimeric antigen receptor T (CAR-T) cell immunotherapy. For each treatment, researchers showed that the organoid responses are different and effectiveness is correlated to their genetic mutations in patient tumors. This model opens the possibility for future clinical trials for personized treatment based on individual patient tumor responses to various different drugs.

Notably, the researchers observed a benefit in the organoids treated with CAR T therapies, which have been used in ongoing clinical trials to target the EGFRvIII mutation, a driver of the disease. In six GBOs, the researchers showed specific effect to patient GBOs with the EGFRvIII mutation with an expansion of CAR T cells and reduction in EGFRvIII expressing cells.

"These results highlight the potential for testing and treating glioblastomas with a personalized approach. The ultimate goal is to work towards a future where we can study a patient's organoid and test which CAR T cell is going to be the best against their tumor, in real time." O'Rourke said. "A shorter-term goal, given the heterogeneity of glioblastomas, is that in vitro testing of various therapeutic options may also help refine patient enrollment in clinical trials, by more accurately defining mutations and selecting the appropriate, available targeted therapies for each."

Here is the original post:
Brain tumor organoids may be key to time-sensitive treatments for glioblastomas - Science Codex

Health care in America is dysfunctional but its lack of transparency is downright dangerous – NBC News

Wow, you survived cancer? What's your secret to health care?

As absurd as that sounds, its a question many Americans who get sick are still asking as we ring in the year 2020. Getting health care in this country is still so circuitous it often does feel like a secret a maze deciphered in private that's never quite mastered. The reward for solving it? Perhaps your life; perhaps the loss of your life savings. And thats if youre lucky.

Even with the Affordable Care Act, almost 30 million are without health insurance in the U.S. And if youve perused plans on the ACA marketplace, youll know why. Theyre pricey, and a new year brings fears that insurance premiums are once again rising. (Who knew the inflation rates on a pap smear were that high?!) Meanwhile, 14 Republican-led states are still refusing to expand Medicaid as stipulated in the ACA, even though the federal government would pay for 90 percent of the cost. Why? Something about repeal and replace or socialism. Its hard to keep track.

Even with the Affordable Care Act, almost 30 million are without health insurance in the U.S. And if youve perused plans on the ACA marketplace, youll know why.

I traveled to three states, each with their own unique health care access challenges, for my new MSNBC special "Red, White, and Who? Between Texas, New York and Utah there are major differences in how easy it is to see a doctor without going bankrupt. But every single person I spoke with regardless of job, socioeconomic status or even political affiliation had one identical anxiety: healthcare in one of the most advanced countries in the world is ridiculously, hopelessly complicated.

Get the think newsletter.

Im retired, but I feel like a have a job, Larry Chiuppi told me sitting outside at an RV park in Houston, blocks from one of the top cancer treatment hospitals in the country. Larry has been caring for his wife Nancy Raimondi, who has blood cancer, for over a year. During that time, he himself was diagnosed with prostate cancer. Even with her Medicare and his private health plan under the ACA, navigating the billing systems for the endless hospital visits, specialists and tests each with their own separate charges requires a huge amount of time and vigilance. He tells me they once got a $14,000 bill for a stem cell transplant because someone forgot to link Nancys Medicare. Larry imagined many people wouldve just tried to pay it. And most Americans dont have a retirees free time and Larrys persistence to help them through the bureaucracy, an added burden of getting well.

We also dont all have a mother like Sandra Stein. She and her family live in New York, a state where the uninsured population is less than five percent, and 6.5 million are on Medicaid. I met Sandra on a street corner in upper Manhattan, where activists were flyering for the New York Health Act, a bill that would give every New Yorker state-funded care. Sandra believes in single-payer healthcare because she has experienced the mind-numbing labyrinth that is the private insurance system firsthand.

When her son was nearly three, he developed a rare neurological disease that left him unable to walk or speak. At the time, she and her husband had private insurance, which was relatively good insurance, according to Sandra. But that didnt make things easier. When they first went to the hospital in an ambulance, the doctors there didnt take their insurance even though the hospital did. Her son ultimately stayed in three different hospitals over the course of 15 months.

When we got home it was my job to figure out the pile of bills and the collections threats, she told me. Its been eight years, but Sandras voice cracked like the memory happened yesterday. I couldnt imagine how hard it mustve been to be afraid for your childs life while collections agents breathed down your neck. Sandra says the billing department sought her out even while her son was in the ICU, and that there were so many billing errors that she ultimately asked for an audit.

And yet, Sandra, Larry and Nancy are the lucky ones. They have health insurance, and they have the time and resources to be able to make their way through the bureaucratic hall of mirrors and toward a fighting chance at getting well.

Its this cruel opacity of the private insurance system, on top of the rising monthly costs of just having a plan, that can be the difference between life and death. And it keeps a surprising number of Americans away from the system altogether. Like a rodeo cowboy I met in Texas, whose story youll just have to watch (Im not spoiling it all!). Its also led Americans like Sandra to believe that a massive simplification of our health care system is far overdue.

For many, that simplification comes in the form of cutting out the profit motive and moving toward government-funded insurance, like Medicare for All, which Big Pharmas enemy number one Sen. Bernie Sanders and I hashed out over bagels in a New York City deli.

Ultimately what became clear through my travels is that healthcare in America is often overpriced and even dysfunctional, but its the lack of transparency that can be the most insidious. You pretty much have to be a health care policy expert, or have a loved one who can quit their job to become one, in order to ensure proper help.

Its also strange that in a country that loves the free market as much as we do, we the consumer have no idea how much anything costs when we walk into a hospital. Why would we? Our health is priceless, so we are simply at the mercy of an ineffective system. That is, unless we fight for something different.

Red, White, and Who premieres on MSNBC on Dec. 29 at 9 p.m. E.T.

Francesca Fiorentini is journalist and comedian. She is the host of "Red, White and Who?" on MSNBC and Newsbroke on AJ+. Follow her @franifio.

See the article here:
Health care in America is dysfunctional but its lack of transparency is downright dangerous - NBC News

Animal Stem Cell Therapy Market Research Report 2026 Observational Studies With Top Manufacturers – Market Research Sheets

The Animal Stem Cell Therapy Market is expected to increase more and rapidly, claims the latest report added by SMI.

Animal Stem Cell Therapy Market Outlook from 2019 to 2026. The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Animal Stem Cell Therapy market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Animal Stem Cell Therapy market. The report offers an overview of the market, which briefly describes the market condition and the leading segments. It also mentions the top players present in the global Animal Stem Cell Therapy market.

Click to Download Free Global Animal Stem Cell Therapy Market Research Sample PDF Copy Here: https://www.stratagemmarketinsights.com/sample/15082

This comprehensive Animal Stem Cell Therapy research report encompasses a brief on these trends, size, share that can assist the institutions, organizations, corporations, and individuals functioning in the industry to know the Animal Stem Cell Therapy market and strategize for their business growth accordingly. The research report breakdowns the market size, industry share, growth, key segments, CAGR, Application, Type, Application and key drivers.

To comprehend Global Animal Stem Cell Therapy market dynamics in the world mainly, the worldwide Animal Stem Cell Therapy market is analyzed across major global regions. Stratagem Market Insights also provides customized specific regional and country-level reports for the following areas.

North America(United States, Canada & Mexico)Asia-Pacific(Japan, China, India, Australia, etc)Europe(Germany, UK, France, etc)Central & South America(Brazil, Argentina, etc)Middle East & Africa(United Arab Emirates, Saudi Arabia, South Africa, etc)

Geographical Analysis

In order to get a deeper view of Market Size, competitive landscape is provided i.e. Revenue (Million USD) by Players (2014-2019), Revenue Market Share (%) by Players (2014-2019) and further a qualitative analysis is made towards market concentration rate, product/service differences, new entrants and the technological trends in future.

Key highlights from the Study:

1) Any Value Addition Chapters to Provide out of box Assessment?

Market Concentration: Includes C4 Index, HHI, Comparative Market Share Analysis (Y-o-Y), Major Companies, Emerging Players with Heat Map Analysis

Market Entropy: It will provide the randomness of the market which will help you understand the markets aggressiveness; players constantly do expansions, technological advancement, M&A, joint ventures.

Patent Analysis: To overcome competition, players constantly make R&D expenses and to better evaluate uncertain growth scenarios of market players and overall industry a patent analysis chapter introduces which will provide insights like no. of patents issued by players each year.

Peer Analysis: An evaluation of peer to peer analysis by key financial metrics such as EBITDA Margin, Net Profit Margin, Gross Margin, Total Revenue, Segmented Market Share, Assets, etc.

Grab Exclusive Discount on Animal Stem Cell Therapy Market Research @ https://www.stratagemmarketinsights.com/discount/15082

2) How Companies are profiled in the report?

A detailed assessment is done on the list of companies taken into consideration by following certain industry standards to reach the most relevant profile or manufacturers. More emphasis is given on SMEs that are emerging and evolving in the market with their product presence and technological upgraded modes, players that are also part of the study taken from a vast list.

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

3) Can we add or profiled a new company or customize the list of companies in the final study?

Yes, we can add or profile a new company as per client needs in the final report. Final confirmation will be provided by the research team depending upon the difficulty of the survey.

** Data availability will be confirmed by research in the case of a privately held company. Few players can be added at no added cost.

4) What details will the competitive landscape will provide?

A value proposition chapter to help you understand what level of business strategies key players are involved along with investment and deal size to gauge market. 2-Page profiles for all listed manufacturers along with 3 years of financial data to evaluate their overall performance in the market along with business overview, product specification, headquarter details, etc.

5) What all regional segmentation covered? Can a specific country of interest be added?

Currently, the research report gives special attention and focus on the following regions:

Asia-Pacific, North America, Europe, South America & Middle East & Africa

** Countries of specific interest can be included.

6) Can the inclusion of additional Segmentation / Market breakdown is possible?

Yes, the inclusion of additional segmentation / Market breakdown is possible subject to data availability and difficulty of survey. However, a detailed requirement needs to be shared with our research before giving final confirmation to the client.

** Depending upon the requirement the deliverable time may vary.

Contact us if any queries before the purchase on this report @ https://www.stratagemmarketinsights.com/quiry/15082

About Us:

Stratagem Market Insights is a management consulting organization providing market intelligence and consulting services worldwide. We bring the expertise of consultants with a cumulative industry experience of more than 70 years. The firm has been providing quantified B2B research and currently offers services to over 350+ customers worldwide. Our reports cover various end-use industries such as Aerospace and Defense, Agriculture, Food and Beverages, Automotive, Chemicals and Materials, Consumer Goods and Retail, Electronics, Energy, Mining, and Utilities, Pharmaceuticals, Manufacturing and Construction, Services, and Healthcare, and ICT.

For More Related Reports: CLICK HERE

This post was originally published on Market Research Sheets

Visit link:
Animal Stem Cell Therapy Market Research Report 2026 Observational Studies With Top Manufacturers - Market Research Sheets

Stem Cell Alopecia Treatment Market Segmentation, Top Companies, Applications, Comprehensive Research Report and Forecast to 2026 – Market Research…

The recent report added by Verified Market Research gives a detailed account of the drivers and restraints in the Global Stem Cell Alopecia Treatment market. The research report, titled [Global Stem Cell Alopecia Treatment Market Size and Forecast to 2026] presents a comprehensive take on the overall market. Analysts have carefully evaluated the milestones achieved by the global Stem Cell Alopecia Treatment market and the current trends that are likely to shape its future. Primary and secondary research methodologies have been used to put together an exhaustive report on the subject. Analysts have offered unbiased outlook on the global Stem Cell Alopecia Treatment market to guide clients toward a well-informed business decision.

The comprehensive research report has used Porters five forces analysis and SWOT analysis to give the readers a fair idea of the direction the global Stem Cell Alopecia Treatment market is expected to take. The Porters five forces analysis highlights the intensity of the competitive rivalry while the SWOT analysis focuses on explaining strengths, weaknesses, opportunities, and threats present in the global Stem Cell Alopecia Treatment market. The research report gives an in-depth explanation of the trends and consumer behavior pattern that are likely to govern the evolution of the global Stem Cell Alopecia Treatment market.

The following Companies as the Key Players in the Global Stem Cell Alopecia Treatment Market Research Report:

Regions Covered in the Global Stem Cell Alopecia Treatment Market:

Europe (Germany, Russia, UK, Italy, Turkey, France, etc.)

The Middle East and Africa (GCC Countries and Egypt)

North America (United States, Mexico, and Canada)

South America (Brazil etc.)

Asia-Pacific (China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The scope of the Report:

The research report on global Stem Cell Alopecia Treatment market includes segmentation on the basis of technology, application, end users, and region. Each segmentation is a chapter, which explains relevant components. The chapters include graphs to explain the year-on-year progress and the segment-specific drivers and restraints. In addition, the report also provides the government outlooks within the regional markets that are impacting the global Stem Cell Alopecia Treatment market.

Lastly, Verified Market Researchs report on Stem Cell Alopecia Treatment market includes a detailed chapter on the company profiles. This chapter studies the key players in the global Stem Cell Alopecia Treatment market. It mentions the key products and services of the companies along with an explanation of the strategic initiatives. An overall analysis of the strategic initiatives of the companies indicates the trends they are likely to follow, their research and development statuses, and their financial outlooks. The report intends to give the readers a comprehensive point of view about the direction the global Stem Cell Alopecia Treatment market is expected to take.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15102&utm_source=MRS&utm_medium=002

Table of Content

1 Introduction of Stem Cell Alopecia Treatment Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Stem Cell Alopecia Treatment Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Stem Cell Alopecia Treatment Market, By Deployment Model

5.1 Overview

6 Stem Cell Alopecia Treatment Market, By Solution

6.1 Overview

7 Stem Cell Alopecia Treatment Market, By Vertical

7.1 Overview

8 Stem Cell Alopecia Treatment Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Stem Cell Alopecia Treatment Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report @ https://www.verifiedmarketresearch.com/product/stem-cell-alopecia-treatment-market/?utm_source=MRS&utm_medium=002

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

This post was originally published on Market Research Sheets

Read the original:
Stem Cell Alopecia Treatment Market Segmentation, Top Companies, Applications, Comprehensive Research Report and Forecast to 2026 - Market Research...

Stem Cell Cartilage Regeneration Market Key players, Geographical Regions and Growth Analysis Outlook Up To 2028 – Sound On Sound Fest

New York City, NY: December 2019 Published via (Wired Release) If you are involved in the Stem Cell Cartilage Regeneration industry or intend to be, then this examine will offer you a comprehensive outlook. Its vital statistics to preserve your market expertise as much as date.

The global Stem Cell Cartilage Regeneration Market Research Report 2019-2028 accommodates a treasured bunch of data that light up the most critical sectors of the Stem Cell Cartilage Regeneration market. The statistics available in the file delivers all-inclusive facts approximately the Stem Cell Cartilage Regeneration marketplace, which is understandable for an expert. The global Stem Cell Cartilage Regeneration marketplace file provides data concerning all of the aspects associated with the marketplace, which incorporates opinions of the very last product, and the key factors hampering the market growth. It suggests how distinctive gamers are competing within the global Stem Cell Cartilage Regeneration market and discusses strategies theyre using to distinguish themselves from other participants.

To Comprehend The Complete Report Through TOC, Figures, and Tables, Get Free Sample Copy (Download PDF) @https://marketresearch.biz/report/stem-cell-cartilage-regeneration-market/request-sample

The geographical division offers statistics that offer you a concept of the revenue of the groups and sales figures of the Stem Cell Cartilage Regeneration For boom business. Here are highlights of the Geographical Divisions: Asia-Pacific (China, Japan, Korea, India, and Southeast Asia and more), North America (United States, Canada, and Mexico), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa), South America (Brazil, Argentina, Colombia), Europe (Germany, Spain, France, UK, Russia and Italy and more) and ROW (Rest-of-the-World).

Global Stem Cell Cartilage Regeneration Market 2019-2028 Competitive Landscape:-

A variety of leading gamers mention inside the Global Stem Cell Cartilage Regeneration Market research document are focusing on increasing operations in regions, as they exhibit ability business opportunities. The Global Stem Cell Cartilage Regeneration Market record classifies the marketplace dynamics and trends in the international and regional markets considering several aspects together with technology, supplies, capacity, production, profit, and price.

The document reviews the aggressive landscape scenario seen amongst top Stem Cell Cartilage Regeneration Sales players, their employer profile, revenue, sales, business tactics, and forecast Stem Cell Cartilage Regeneration Sales industry situations. According to the research, Stem Cell Cartilage Regeneration Sales marketplace is rather competing and disparate because of worldwide and neighborhood vendors. The global Stem Cell Cartilage Regeneration Sales marketplace record chiefly includes following players- Companies

Segmentation of Global Stem Cell Cartilage Regeneration Market:

Segmentation by stem cell type:

Hematopoietic Stem Cells (HSCs)Pluripotent Stem Cells (iPSC/ESCs)Mesenchymal Stem Cells (MSCs)Segmentation by treatment:

MicrofractureOsteochondral TransplantAutologous Chondrocyte ImplantationStem Cell InjectionsSegmentation by end user:

Hospitals & ClinicsAmbulatory Surgical Centers

Have Any Query? Ask Our Expert @https://marketresearch.biz/report/stem-cell-cartilage-regeneration-market/#inquiry

Global Stem Cell Cartilage Regeneration Market 2019-2028 : Research Methodology

A Detailed Study of Stem Cell Cartilage Regeneration Market includes the assessment of PORTERS Five Forces Analysis, PESTLE Analysis, Product Life Cycle Analysis, with Opportunity Maps. These analysis strategies can permit you to establish the highest competitive forces to form your business and to work out organization strategy. In this research study, we gathered, analyzed and interpreted records approximately Stem Cell Cartilage Regeneration market, approximately a product and its services, about the beyond and present commercial enterprise targets. This Market research includes two forms of data: Primary data which includes An institution survey and The in-depth interviews, Secondary Research Information assembled by means of media sources, exchange associations, government agencies, chambers of commerce, exertions unions, and so on. Secondary studies normally published in newsletters, pamphlets, magazines, alternate publications, and newspapers.

Highlights of Report:

1. Distribution Channel Assessment

2. Latest and Future Innovation Trends

3. Competitive Strategies

4. Niche Market Trends

5. Market Entry Analysis

6. Market Size and Forecasts

How is this Report On Stem Cell Cartilage Regeneration Market Useful?

In order to realize the understanding and insights acquired from this report, a few figures and presentations are also included other than the data. These are in the shape of charts, graphs, tables, etc. Rather than studying the raw data, studying through the equipment is less complicated and greater conclusions can be drawn looking at these explaining diagrams.

This report also offers hands-on ready-to-get right of entry to analytical facts furnished by enterprise professionals. They can recognize various essential trends, drivers, and demanding situations in the Stem Cell Cartilage Regeneration industry. This report will provide a detailed assessment of majorly the fundamental players, areas considered, and applications.

Contact Us:

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:inquiry@marketresearch.biz

See the original post:
Stem Cell Cartilage Regeneration Market Key players, Geographical Regions and Growth Analysis Outlook Up To 2028 - Sound On Sound Fest

Scientists race to use zero gravity to kill the worst cancers – Big Think

Can being in zero gravity help beat cancer? A growing field of research, including an upcoming research mission to the International Space Station, is hoping to prove just that.

Joshua Chou, a biomedical engineer from the University of Technology Sydney in Australia, has conducted successful trials in a lab environment, and aims to establish that zero-g can kill cancer cells.

Zero gravity or weightlessness occurs in the absence of the sensation of weight, when no contact forces act upon an object (or a body).

Chou's work looks to pinpoint the sensors by which cancer cells find each other and grow into tumors within a body. He thinks these receptors are dependent on gravity and once it's removed, the cancer can be stopped as the cells won't be able to "sense" each other.

To study this approach further, a graduate student working with Chou created the first microgravity device in Australia. The apparatus is a tissue box-sized spinning container. The researcher described it as "something that looks like the pods astronauts train in."

Joshua Chou with a prototype of Australia's first microgravity device.

Photo by Sissy Reyes.

The device has allowed Chou's team to investigate how microgravity affects different diseases. The scientists report it has been tremendously effective so far in eliminating cancer cells.

Normally, these are the hardest cancers to fight. Chou's experiments, without using any drugs, managed to either kill such cells or make them "float off because they can no longer hold on."

Early in 2020, Chou and his team will be able to test their approach in space, launching a specially-designed module with the help of SpaceX. The module will be loaded with the four types of cancer cells (ovarian, breast, nose and lung). Once launched, the scientists will be able to monitor it from Earth via data feeds. The experiment is set to last seven days, after which the cells will be frozen and send back to Earth 21 days later on a shuttle. More studies will be conducted once the cells are back in the lab on the ground.

The research team, from left, Chelsea Ly, Carin Basirun, Jessica Domingo and Joshua Chou.

Photo: Joshua Chou.

If Chou and his team succeed, does that mean cancer patients will be sent to space for treatment? While there may be such eventualities as well, Chou's vision is to develop a drug that patients can take while on Earth. He hopes to use it to "trick" cancer cells into behaving like they are in space.

Chou also thinks that this kind of therapy might not be a "magic bullet" that will work on its own, but rather in conjunction with existing treatments. "It could give current treatments like chemotherapy a big enough boost to kill the disease," he adds in a recent article.

Chou's research is not the only one of its kind. Nine research projects are going to study the effects of weightlessness on cancer aboard the new China Space Station (CSS), set for 2022. One such project is "Tumours in Space" that will look at how microgravity and cosmic radiation can affect the growth of tumors.

Tricia L. Larose from the Norwegian University of Science and Technology, who is the project's Principal Investigator, explained their goal:

Organoids are three-dimensional cancerous tumors that can form small structures mimicking different organs.

Scientists in other countries are also looking at utilizing gravity on cancer. In 2017, a German team, led by professor Daniela Grimm from the University of Magdeburg, studied the effects of space on thyroid cancer cells. This was, in fact, the third time Grimm's team sent such samples into space. Their objective, as Grimm expressed in an interview, is "to find growth-regulating proteins and certain receptors that express and secrete differently in space versus on Earth." If they can find such proteins and receptors, they can develop new drugs to treat the cancers back on our home planet.

The Influence of short-term #Microgravity on Human Prostate CancerThe Influence of short-term #Microgravity on Human Prostate Cancer Cells during a Parabolic Flight . By Prof. Daniela Grimm from University of Magdeburg . Dr...

Related Articles Around the Web

See the original post here:
Scientists race to use zero gravity to kill the worst cancers - Big Think

How technology has changed the world in the last decade – The Upcoming

How technology has changed the world in the last decade

Technology has changed the world in many ways during the last decade. Medicine- technology has enabled robots and remote location surgeries, it has reduced the chances of infection and disease, it has speeded up the process of delivering medicines and life-saving drugs.

Every day, technology is creating more breakthroughs to fight serious illnesses that have resulted in high mortality in the past. Stem cell research gives patients a new lease on life, as do artificial limbs.

Travelling

Gone are the days when we stood in line for tickets. No more talking on the phone with the travel agent for good deals. Now, travel is online and forever changed. You can go online to research your destination and find information you need. From where to stay to what to wear there, every piece of travel information can be found. Now, you can track a flight, train or car, you can use GPS to find a destination, you can book and cancel tickets online and plan your trip down to the exact minute.

Finance

When was the last time you went to a bank to pull out money or update your passbook? Hard to remember, isnt it? Technology has made the world of banking and finance accessible for everyone. You can do all your banking transactions online, keep an eye on your stock portfolio, and invest in funds of your liking.

Shopping and gaming

More and more people are choosing to shop online. Thanks to technology, huge retail chains have websites where you can buy anything from a pin to a plane. Customers are spoilt for choice, deals are almost irresistible, and delivery is hassle-free.

From fantasy league football to watching matches with high speed internet, the world of games and play has changed forever. Online gaming is exploding and gaining popularity every day. There are thousands and thousands of sites and apps offering new ways to experience games. Technology has brought all sorts of games, from augmented reality to even real money blackjack right to your home, to play, practise and excel.

Conservation

A vital topic on todays world, conservation efforts have benefitted from technology. From drone technology to monitor animals and birds, to embedded chips to keep track of movements and births, technology is helping dedicated people everywhere make the planet a better place. Ocean currents, rising temperatures, glacier cleavages, deforestation and afforestation- technology is helping us keep track of nature.

Entrepreneurship

There was a time when small and medium enterprises could not operate beyond local sales. Now, these sites have websites and more people are getting to know of them and their products and services. Companies have clients from all over the world, bringing valuable experience and expertise in its wake.

Social media

Social media has defined the decade for sure. From influencer behaviour, to finding new friends, social media presence has been ubiquitous. Instagram is a visual delight, Twitter is for clever repartee, and YouTube channels can teach you everything from how to cook to how to pitch a tent.

The editorial unit

Read the original:
How technology has changed the world in the last decade - The Upcoming